No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Long Acting Muscarinic Antagonist (LAMA) market is a subset of the larger respiratory drug market. LAMAs are used to treat chronic obstructive pulmonary disease (COPD) and asthma. These drugs work by blocking the action of acetylcholine, a neurotransmitter that causes airway constriction. This helps to reduce symptoms such as coughing, wheezing, and shortness of breath. LAMAs are typically administered via inhalation, and are available in both short-acting and long-acting formulations. Long-acting formulations provide sustained relief from symptoms over a longer period of time.
Some of the major companies in the LAMA market include GlaxoSmithKline, Boehringer Ingelheim, AstraZeneca, Novartis, and Merck. These companies produce a variety of LAMA drugs, including tiotropium, aclidinium, umeclidinium, and glycopyrronium. Show Less Read more
